- American City Business Journals•9 hours ago
Sanofi-Genzyme, which expects to soon win approval for an eczema drug, has filed a federal lawsuit that seeks to preempt a possible patent challenge by Amgen. The Cambridge-based firm, a unit of French pharmaceutical giant Sanofi SA (SNY), filed a suit in Boston federal court along with its partner Regeneron Pharmaceuticals (REGN). The complaint asks a judge to rule that the drug does not infringe a patent held by Amgen (AMGN).
- Zacks•11 hours ago
Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).
- Investopedia•11 hours ago
Regeneron Pharmaceuticals, Inc. REGN and its partner Sanofi SNY announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis ...
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||45.22 - 45.47|
|52 Week Range||36.81 - 45.95|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.40|
|Dividend & Yield||1.58 (3.48%)|
|1y Target Est||N/A|